Mast cell activation syndrome: A review

Current Allergy and Asthma Reports

Volumn 13, Issue 1, 2013, Pages 27-32

  Frieri, Marianne ^a   Patel, Reenal ^a   Celestin, Jocelyn ^b  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Classification; Clonal MCAD; Idiopathic anaphylaxis; Mast cell activation; Mast cell activation syndrome; Mastocytosis; Nonclonal MCAD; Treatment

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; HISTAMINE; HISTAMINE DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PROSTAGLANDIN D2; TRYPTASE;

ABDOMINAL CRAMP; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BASOPHIL; CARDIOVASCULAR SYSTEM; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL FEATURE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE SEVERITY; DIURESIS; DIZZINESS; DYSPNEA; ENZYME BLOOD LEVEL; EYE INFECTION; FAINTNESS; FLUSHING; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HEADACHE; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; IMMUNOPATHOLOGY; INTEGUMENTARY SYSTEM; LABORATORY DIAGNOSIS; MAST CELL; MAST CELL ACTIVATION SYNDROME; MAST CELL LEUKEMIA; MEDIATOR RELEASE; MEDICAL DOCUMENTATION; NAUSEA; NERVOUS SYSTEM; NOSE DISEASE; OXIDATIVE STRESS; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRACTICE GUIDELINE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PRURITUS; REFERENCE VALUE; RESPIRATORY SYSTEM; SYSTEMIC MASTOCYTOSIS; TACHYCARDIA; TREATMENT RESPONSE; URINALYSIS; URINE LEVEL; URTICARIA; VALIDATION PROCESS; VOMITING; WHEEZING;

ANIMALS; HISTAMINE; HUMANS; LEUKOTRIENES; MAST CELLS; MASTOCYTOSIS; PROSTAGLANDIN D2; SYNDROME;

EID: 84872596950     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-012-0322-z     Document Type: Article

References (31)

1. Kinet J-P. The high affinity receptor for IgE. Curr Opin Immunol. 1990;2:499-505.
2. Cambier JC. Antigen and Fc receptor signaling: the awesome power of the immunoreceptor tyrosine based activation motif (ITAM). J Immunol. 1995;155:3281-5.
3. Fukamachi H, Kawakami Y, Takei M, et al. Association of protein tyrosine kinase with phospholipase C-γ1 in bone marrow-derived mouse mast cells. Proc Natl Acad Sci USA. 1992;89:9524-8.
4. Bischoff SC, Dahinden CA. c-Kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med. 1992;175:237-44.
5. Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol. 1993;142(4):965-74. (Pubitemid 24060571)
6. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol. 1994;55:1-96.
7. Lukacs NW, Strieter RM, Lincoln PM, et al. Stem cell factor (c-kit ligand) influences eosinophil recruitment and histamine levels in allergic airway inflammation. J Immunol. 1996;156(10):3945-51. (Pubitemid 26137682)
8. Bingham III CO, Austen KF. Mast-cell responses in the development of asthma. J Allergy Clin Immunol. 2000;105(2 Pt 2):S527-34.
9. Iemura A, Tsai M, Ando A, et al. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol. 1994;144(2):321-8. (Pubitemid 24165953)
10. Meninger CJ, Yano H, Rottapel R, et al. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood. 1992;4:958-63.
11. Ito T, Smrž D, Jung MY, et al. Stem cell factor programs the mast cell activation phenotype. J Immunol. 2012;188(11):5428-37.
12. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. J Immunol Rev Immunol Rev. 2009;228(1):149-69.
13. Bai Y, Bandara G, Ching Chan E. Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation. Leukemia. 2012. doi: 10.1038.
14. Bax HJ, Keeble AH, Gould HJ. Cytokinergic IgE action in mast cell activation. Front Immunol Inflamm Vol; 2012 (3) 8
15. •• Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126:1099-104. This excellent paper explored and proposed criteria for the diagnosis of the mast cell activation syndrome. The proposed criteria was discussed in the context of other disorders involving mast cells or with similar presentations and as a basis for further scientific study and validation.
16. Shibao C, Arzubiaga C, Roberts 2nd LJ, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45(3):385-90. (Pubitemid 40315808)
17. Frieri M. Mastocytosis. In: Massoud Mahmoud editor. Challenging Cases in Allergy and Immunology, Chapter 14. Humana Press; 2009. pp 201-212.
18. Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood. 2007;110:2331-3. (Pubitemid 47523152)
19. Koterba AP, Akin C. Differences in the clinical presentation of anaphylaxis in patients with indolent systemic mastocytosis (ISM) versus idiopathic anaphylaxis (IA). J Allergy Clin Immunol. 2008;121:S68. abstract.
20. An Updated Practice Parameter. In: Lieberman P et al., editor. Idiopathic Anaphylaxis. The Diagnosis and Management of Anaphylaxis. 2005;115; 3:S483-S523.
21. • Frieri M. Anaphylaxis. Chapter 68. In: Manual of critical care. Philadelphia: American College of Physicians; 2009. p. 721-30. This chapter reviewed the etiology, incidence, unusual manifestations, differential diagnosis, pathogenesis, prevention and treatment of anaphylaxis with a comprehensive table of mast cell and basophil mediators and clinical findings in anaphylaxis and anaphylactoid reactions.
22. Frieri M, Alling DW, Metcalfe DD. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. Am J Med. 1985;78:9-14. (Pubitemid 15159611)
23. Metcalfe DD. Differential diagnosis of the patient with unexplained flushing/anaphylaxis. Allergy Asthma Proc. 2000;21(1):21-4.
24. Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010;125(6):1269-78.
25. Molderings G, Brettner S, Homann J, Afrin L. Mast cell activation disease: a concise practical guide for diagnostic work up and therapeutic options. J Hematol Oncol. 2011;4:10.
26. Hamilton MJ, Hornick JL, Akin C, et al. A newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128(1):147-52.
27. •• Valent P, Akin C, Arock M, et al. Definitions, criteria & global classification of MC disorders with special reference to MCAS: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-25. This excellent paper proposed a global unifying classification of all MC disorders and pathologic MC reactions which included three types of 'MCA syndromes' (MCASs), namely primary MCAS, secondary MCAS, and idiopathic MCAS. It assisted in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or over interpretation of clinical symptoms in daily practice.
28. Pardanani A. Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(4):401-11.
29. Frieri M, Linn N, Schweitzer M, Angadi C, et al. Lymphadenopathic mastocytosis with eosinophilia and biclonal gammopathy. J Allergy Clin Immunol. 1990;86:l26-l132. (Pubitemid 20226853)
30. Gotlib J, Akin C. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. Semin Hematol. 2012;49(2):128-37.
31. Patel R, Celestin J, Frieri M. An unusual case of mast cell activation syndrome. J Allergy Clin Immunol, abs #475, 2012.